Patents by Inventor John E. Edwards

John E. Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10857216
    Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: December 8, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, John P. Hennessey, Jr., Michael Timothy Cooke, Jack D. Sobel
  • Patent number: 10653757
    Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: May 19, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael R. Yeaman, John E. Edwards, Jr., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, Jr.
  • Publication number: 20190194301
    Abstract: The invention provided Mucorales CotH antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The Mucorales CotH antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Application
    Filed: December 11, 2018
    Publication date: June 27, 2019
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Teklegiorgis Ghebremariam, Yue Fu, John E. Edwards, Scott Filler
  • Patent number: 10300120
    Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: May 28, 2019
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Ashraf S. Ibrahim, Bradley J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
  • Publication number: 20190030141
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Application
    Filed: October 11, 2018
    Publication date: January 31, 2019
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, JR., John P. Hennessey, JR.
  • Patent number: 10160790
    Abstract: The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 25, 2018
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, John E. Edwards, Jr., Guanpingsheng Luo, Yue Fu
  • Patent number: 10130691
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 20, 2018
    Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
  • Patent number: 9581020
    Abstract: A downhole tool is conveyed within a borehole extending into a subterranean formation. A void is created in a sidewall of the borehole by extending a rotating member from the downhole tool into the sidewall. A portion of the sidewall surrounding the void is mechanically compressed, and the viscosity of hydrocarbons in the subterranean formation proximate the void is reduced by injecting a fluid from the downhole tool into the formation via the void. Fluid comprising the reduced viscosity hydrocarbons and the injected fluid may then be drawn from the subterranean formation into the downhole tool.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: February 28, 2017
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: John E. Edwards, Adrian Rodriguez Herrera, Morten Kristensen, Tobias Judd, Andrew E. Pomerantz, Oliver Clinton Mullins
  • Patent number: 9364539
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 14, 2016
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
  • Publication number: 20160130330
    Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragments, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.
    Type: Application
    Filed: January 8, 2016
    Publication date: May 12, 2016
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Brad J. Spellberg, Scott Filler, Yue Fu, John E. Edwards
  • Patent number: 9279002
    Abstract: The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 8, 2016
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Teklegiorgis Ghebremariam, Yue Fu, John E. Edwards, Scott Filler
  • Patent number: 9259467
    Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 16, 2016
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Brad Spellberg, Scott Filler, Yue Fu, John E. Edwards
  • Publication number: 20150273031
    Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
    Type: Application
    Filed: July 20, 2012
    Publication date: October 1, 2015
    Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Michael R. Yeaman, John E. Edwards, JR., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, JR.
  • Publication number: 20150191514
    Abstract: The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 9, 2015
    Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, John E. Edwards, JR., Guanpingsheng Luo, Yue Fu
  • Publication number: 20140353479
    Abstract: A downhole tool is conveyed within a borehole extending into a subterranean formation. A void is created in a sidewall of the borehole by extending a rotating member from the downhole tool into the sidewall. A portion of the sidewall surrounding the void is mechanically compressed, and the viscosity of hydrocarbons in the subterranean formation proximate the void is reduced by injecting a fluid from the downhole tool into the formation via the void. Fluid comprising the reduced viscosity hydrocarbons and the injected fluid may then be drawn from the subterranean formation into the downhole tool.
    Type: Application
    Filed: January 14, 2013
    Publication date: December 4, 2014
    Inventors: John E. Edwards, Adrian Rodriguez Herrera, Morten Kristensen, Tobias Judd, Andrew E. Pomerantz, Oliver Clinton Mullins
  • Publication number: 20140335114
    Abstract: The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.
    Type: Application
    Filed: April 17, 2014
    Publication date: November 13, 2014
    Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Yue FU, Guanpingsheng Luo, Ashraf S. Ibrahim, Brad Spellberg, John E. Edwards, JR.
  • Patent number: 8790662
    Abstract: The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: July 29, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Brad J. Spellberg, Ashraf S. Ibrahim, John E Edwards, Jr.
  • Publication number: 20140127243
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Application
    Filed: September 23, 2013
    Publication date: May 8, 2014
    Inventors: John E. Edwards, JR., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
  • Publication number: 20140127217
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Application
    Filed: September 23, 2013
    Publication date: May 8, 2014
    Inventors: John E. Edwards, JR., Scott G. Filler, Danald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
  • Publication number: 20140127218
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Application
    Filed: September 23, 2013
    Publication date: May 8, 2014
    Inventors: John E. Edwards, JR., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg